Biology Atlas

Map / The cascade

step · intermediate · partly written

Dose response

One step of the screening cascade walk-through, from disease to clinic.

What is done

Each hit is tested across a series of concentrations and a four-parameter curve (bottom, top, midpoint, slope) is fitted; the midpoint is reported as an IC50 or EC50. In the STK33 retest, 224 substances were tested at 8 concentrations from 0.1 to 12 uM. A variant, quantitative HTS, titrates every compound inside the primary screen: over 60,000 compounds gave concentration-response curves in one experiment. 123

Reported, not yet replicated

Costs

One 2020 academic recharge sheet prices a dose-response confirmation of 60 compounds at 8 points in duplicate on 3 plates at $1,837 internal and $3,490.30 external, reagents excluded, and a single-concentration triplicate confirmation of 500 compounds on 5 plates at $3,739 internal. No commercial price was found and the sheet is likely out of date. 4

Reported, not yet replicated

Proves

How potent the compound is in this assay and whether its effect rises smoothly with dose; a curve with a visible floor, ceiling and middle supports the number, and its shape is itself evidence. The STK33 retest called 174 of 224 active, and the chosen probe ML281 had an STK33 IC50 of 14 nM. 152

Reported, not yet replicated

Cannot prove

Affinity: for a competitive inhibitor Ki = IC50 / (1 + [S]/Km), so the IC50 moves with substrate level. Not that the effect is on target: a steep Hill slope can flag aggregation (in 3,048 Lilly biochemical assays, 41 of 61 PAINS alerts were enriched at least 1.5-fold for slopes above 2.0). Not comparability across labs: a reanalysis of two large cancer cell-line drug screens found only 2 of 15 shared drugs with a Pearson correlation above 0.6 on AUC (the rebuttal authors' reading). A bell-shaped degrader curve is mis-fitted by a standard sigmoid (vendor statement). 67891011

Reported, not yet replicated

Assays

Regulators require

No regulation read for this atlas says how hits or leads must be found. The first document the regulator requires is the investigational new drug application, whose pharmacology and toxicology section is built from laboratory-animal or in vitro studies on which the sponsor concludes it is reasonably safe to begin trials (21 CFR 312.23(a)(8)). Discovery data reaches the regulator only as the sponsor's own supporting evidence. This is our reading of the rule, not a statement in it. 12

Our inference

ML role

No machine-learning method specific to dose-response fitting was found; curves are fitted by nonlinear least squares. A model trained on IC50 labels also learns their noise and their conditions: our inference from the cited sources, not a tested finding. 297

Our inference

Reports

Scenarios

Modality notes

The unit of dose changes

For siRNA, potency means how few milligrams per kilogram are needed, set by stability and uptake rather than binding strength. For a gene therapy the dose is in vector genomes per kilogram (Zolgensma: 1.1 x 10^14 vg/kg in one infusion), and FDA called the phase 1 titre assay inaccurate and imprecise. For antisense, dose spacing follows how long the drug stays in tissue: a cerebrospinal fluid half-life of 135 to 177 days gives a label interval of months. 13141516

See: siRNA, Gene therapy, Antisense oligonucleotide (ASO)

Reported, not yet replicated

Still open here

Linked from

Sources

  1. PubChem BioAssay AID 2821: STK33 inhibitor retest, 8-point dose response. PubChem (2010). database, not peer reviewed; opened 2026-11-17 all records citing this
  2. GraphPad Prism guide: classic dose-response curve with variable slope. GraphPad. web, not peer reviewed; opened 2026-11-17 all records citing this
  3. Inglese et al.. Quantitative high-throughput screening (qHTS), Inglese et al., PNAS 2006 (abstract via Europe PMC). PNAS (2006). paper; opened 2026-11-17 all records citing this
  4. MSU Assay Development and Drug Repurposing Core recharge rates (file dated 2020-05-27). Michigan State University (2020). report, not peer reviewed; opened 2026-11-17 all records citing this
  5. Weiwer et al.. Weiwer et al. 2012: the STK33 probe ML281 (PMC full text). PubMed Central (2012). paper; opened 2026-11-17 all records citing this
  6. IC50 (Wikipedia). Wikipedia. web, not peer reviewed; opened 2026-11-17 all records citing this
  7. Assay Guidance Manual section 4, 2008 web archive (NCGC). NCGC via UNT web archive (2008). web, not peer reviewed; opened 2026-11-17 all records citing this
  8. Lilly 2018 analysis of PAINS in biochemical assays (PMC full text). PubMed Central (2018). paper; opened 2026-11-17 all records citing this
  9. Safikhani et al.. Safikhani et al., F1000Research 2016: reanalysis of two large cancer cell-line drug screens. F1000Research (2016). paper; opened 2026-11-17 all records citing this
  10. Han. Han, J Biol Chem 2020: hook effect and ternary complex in degraders. Journal of Biological Chemistry (2020). paper; opened 2026-11-17 all records citing this
  11. Genedata: automated analysis of complex biphasic PROTAC dose-response data. Genedata. vendor-page, not peer reviewed; opened 2026-11-17 all records citing this
  12. US Food and Drug Administration. IND content and format (21 CFR 312.23). Electronic Code of Federal Regulations, Title 21, Part 312 (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  13. Foster DJ, et al.. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther (2018). paper; opened 2026-11-17 all records citing this
  14. US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information, revision 6/2026. FDA (2026). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  15. US Food and Drug Administration. FDA Summary Basis for Regulatory Action: Zolgensma (2019). FDA (2019). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
  16. U.S. Food and Drug Administration (label text supplied by the sponsor). SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information (initial US approval 2016, revised 12/2016). FDA Drugs@FDA label archive (2016). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
History of this record (5)

This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.

Order
7
Stage
hit-to-lead
Status
partly written
Last updated
2026-11-17
Record
content/cascade/dose-response.json